Consequently, testing for Jak2 mutations has become a standard component of evaluating patients with sustained high peripheral blood cell counts, organomegaly, unexplained thrombosis, or other symptoms indicative of MPN [4]. This evidence concerns the gene JAK2 and myeloproliferative disorder.